Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial

Main Article Content

Amy Paller
Adelaide A Hebert
John E Jett
Philip M Brown
David S Rubenstein
Stephen C Piscitelli

Keywords

tapinarof, cream, once daily, atopic dermatitis, eczema, adolescents

References

1. Weidinger S and Novak N. Lancet. 2016;387:1109–1122

2. Bieber T. N Engl J Med. 2008;358:1483–1494

3. Carroll CL, et al. Pediatr Dermatol. 2005;22:192–199

4. Lewis-Jones S. Int J Clin Pract. 2006;60:984–992

5. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.vtama.com/docs/DMVT_VTAMA_PI.pdf. Accessed July 2022

6. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229

7. Strober B, et al. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.06.1171

8. Bissonnette R, et al. J Am Acad Dermatol. 2021;84:1059–1067

9. Dermavant DOF [DMVT-505 Th2 Polarization; Apr 2015]

10. Dermavant DOF [DMVT-505 AD Mouse Model; Oct 2016]

11. Smith SH, et al. J Invest Dermatol. 2017;137:2110–2119

12. Kim BE, et al. Allergy Asthma Immunol Res. 2018;10:207–215

13. Peppers J, et al. J Am Acad Dermatol. 2019;80:89–98

14. Paller A, et al. J Am Acad Dermatol. 2021;84:632–638

15. Bissonnette R, et al. Clin Pharmacol Drug Dev. 2018;7:524–531

16. Jett JE, et al. Am J Clin Dermatol. 2022;23:83–91

17. Hanifin JM and Rajka G. Acta Dermatovener (Stockholm) Suppl. 1980;92:44–47

Most read articles by the same author(s)

1 2 > >>